Clinics in Dermatology
Volume 26, Issue 5 , Pages 432-437 , September 2008

Topical treatments in psoriasis: today and tomorrow

References 

  1. Finlay AY, Ortonne JP. Patient satisfaction with psoriasis therapies: an update and introduction to biologic therapy. J Cutan Med Surg. 2004;8:310–320
  2. Mason J, Mason AR, Cork MJ. Topical preparations for the treatment of psoriasis: a systematic review. Br J Dermatol. 2002;146:351–364
  3. Tremblay J-F, Bissonnette R. Topical agents for the treatment of psoriasis, past, present and future. J Cutan Med Surg. 2002;6:8–11
  4. Lebwohl M, Ting PT, Koo JYM. Psoriasis treatment: traditional therapy. Ann Rheum Dis. 2005;64(Suppl II):ii83–ii86
  5. Van de Kerkhof PCM. The topical treatment of psoriasis. Clin Exp Dermatol. 2005;30:205–208
  6. Van de Kerkhof PCM, Kragballe K. Recommendations for the topical treatment of psoriasis. J Eur Acad Dermatol Venereol. 2005;19:495–499
  7. Dando TM, Wellington K. Topical tazarotene: a review of its use in the treatment of plaque psoriasis. Am J Clin Dermatol. 2005;6:255–272
  8. Durakovic C, Ray S, Holick MF. Topical paricalcitol (19-nor-1a, 25-dihydroxyvitamin D2) is a novel, safe and effective treatment for plaque psoriasis: a pilot study. Br J Dermatol. 2004;151:190–195
  9. Zonneveld IM, Rubins A, Jablonska S, et al. Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study. Arch Dermatol. 1998;134:1101–1102
  10. Bos JD, Meinardi MMHM. The 500 dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol. 2000;9:224–228
  11. Scheinfeld N. The use of topical tacrolimus and pimecrolimus to treat psoriasis: a review. Dermatol Online J. 2004;10:3
  12. Mason AR, Cork MJ, Dooley G, et al. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev. 2006;1:CD005028
  13. Afifi T, de Gannes G, Huang C, Zhou Y. Topical therapies for psoriasis: evidence-based review. Can Fam Physician. 2005;51:519–525
  14. Gulliver WP, Donsky HJ. A report on three recent clinical trials using Mahonia aquifolium 10% topical cream and a review of the worldwide clinical experience with Mahonia aquifolium for the treatment of plaque psoriasis. Am J Ther. 2005;12:398–406
  15. McFerren MA. Useful plants of dermatology: VIII. The false hellebore (Veratrum californicum). J Am Acad Dermatol. 2006;54:718–720
  16. Vali A, Asilian A, Khalesi E, et al. Evaluation of the efficacy of topical caffeine in the treatment of psoriasis vulgaris. J Dermatol Treat. 2005;16:234–237
  17. Kragballe K, Gjertsen BT, De Hoop D, et al. Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet. 1991;337:193–196
  18. Fenton C, Plosker GL. Calcipotriol/betamethasone dipropionate: a review of its use in the treatment of psoriasis vulgaris. Am J Clin Dermatol. 2004;5:463–478
  19. Schön MP, Boehncke WH. Psoriasis. N Engl J Med. 2005;352:1899–1912
  20. In:  Bos JD editors. Skin immune system (SIS): cutaneous immunology and clinical immunodermatology. Boca Raton: CRC Press; 2005;p. 824
  21. Bos JD, De Rie MA, Teunissen MBM, Piskin G. Psoriasis: activation of innate immunity. Br J Dermatol. 2005;152:1098–1107
  22. Balbi A, Anzaldi M, Mazzei M, et al. Synthesis and biological evaluation of novel heterocyclic ionone–like derivatives as anti-inflammatory agents. Bioorg Med Chem. 2006;14:5152–5160
  23. White PJ, Atley LM, Wraight CJ. Antisense oligonucleotide treatments for psoriasis. Expert Opin Biol Ther. 2004;4:75–81
  24. Raoof AA, Chiu P, Ramtoola Z, et al. Oral bioavailability and multiple dose tolerability of an antisense oligonucleotide tablet formulated with sodium caprate. J Pharm Sci. 2004;93:1431–1439
  25. Schäcke H, Rehwinkel H, Asadullah K, Cato ACB. Insight into the molecular mechanisms of glucocorticoid receptor action promotes identification of novel ligands with an improved therapeutic address. Exp Dermatol. 2006;15:565–573
  26. Buttgereit F, Burmester GR, Lipworth BJ. Optimised glucocorticoid therapy: the sharpening of an old spear. Lancet. 2005;365:801–803
  27. Schoepe S, Schäcke H, May E, Asadullah K. Glucocorticoid therapy induced skin atrophy. Exp Dermatol. 2006;15:406–420
  28. Ma Y, Khalifa B, Yee YK, et al. Identification and characterization of noncalcemic, tissue-selective, nonsecosteroidal vitamin D receptor modulators. J Clin Invest. 2006;116:892–904
  29. Guenther LC. Optimizing treatment with topical tazarotene. Am J Clin Dermatol. 2003;4:197–202
  30. Njar VC, Gediya L, Purushottamachar P, et al. Retinoic acid metabolism blocking agents (RAMBAs) for treatment of cancer and dermatological diseases. Bioorg Med Chem. 2006;14:4323–4340
  31. Schiller M, Metze D, Luger TA, et al. Immune response modifiers—mode of action. Exp Dermatol. 2006;15:331–341
  32. Gilliet M, Conrad C, Geiges M, et al. Psoriasis triggered by Toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol. 2004;140:1490–1495
  33. Cristofaro P, Opal SM. Role of Toll-like receptors in infection and immunity: clinical implications. Drugs. 2006;66:15–29
  34. Kumar S, Boehm J, Lee JC. p38 MAP kinases: key signaling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov. 2003;2:717–726
  35. Lin TH, Metzger A, Diller DJ, et al. Discovery and characterization of triaminotriazine aniline amides as highly selective p38 kinase inhibitors. J Pharmacol Exp Ther. 2006;318:495–502

PII: S0738-081X(07)00248-9

doi: 10.1016/j.clindermatol.2007.10.025

Clinics in Dermatology
Volume 26, Issue 5 , Pages 432-437 , September 2008

Article Tools